← Back to Calendar

Relay Therapeutics Q4 2025 Earnings

Relay Therapeutics · $RLAY
Standard Review Earnings
Catalyst Date
February 26, 2026
Date Status
46d ago (past)
Review Type
Standard (10 mo)

Live Company Data NGM

Updated just now · Data: FMP
Current Price
$14.94 +572.97%
+$12.72 today
Day: $14.51 – $15.42
Market Cap
N/A
Shares out: 178.73M
Float: 93.67M
52-Week Range
$2.30
$15.42
Current price is at 96% of 52-week range
Avg Volume
2.77M
Beta
1.58
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $RLAY catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + zovegalisib SERENA-PI3K update

Key Notes

Q4 2025 earnings reported February 26, 2026. Cash: ~$555M at end of Q4 2025. RLY-2608 renamed to zovegalisib following Breakthrough Therapy designation. Initial Phase 1/2 data at ESMO TAT March 16, 2026. Full SERENA-PI3K Phase 2 readout expected H1 2026 (ASCO). Breast cancer triplet data and Phase 3 plans expected 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar